{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:08:06Z","timestamp":1792631286108,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease. Persistent hyperglycemia and metabolic dysregulation promote oxidative stress, reduce nitric oxide bioavailability, and activate inflammatory pathways, thereby accelerating atherosclerosis and cardiovascular complications. Therefore, strategies aimed at restoring endothelial function are crucial to mitigate cardiovascular complications in individuals with cardiometabolic disorders. Among antidiabetic therapies, glucagon-like peptide-1 receptor agonists have demonstrated cardiovascular benefits in large-scale outcome trials, but the underlying mechanisms remain only partially elucidated. In this mini-review, we critically examine both clinical and experimental evidence, with emphasis on the direct effects of glucagon-like peptide-1 receptor agonists on endothelial function. Moreover, we address the heterogeneity within this drug class, noting how differences may contribute to variability in vascular outcomes. By integrating clinical findings with molecular data, this review aims to refine our understanding of the potential endothelial mechanisms underlying cardiovascular protection. Our critical synthesis provides a clearer framework for interpreting the vascular effects of glucagon-like peptide-1 receptor agonists beyond glycemic control, thereby offering a more comprehensive view of their role in managing cardiometabolic disease.<\/jats:p>","DOI":"10.3389\/fmed.2025.1669685","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:00Z","timestamp":1757391480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection"],"prefix":"10.3389","volume":"12","author":[{"given":"Allegra","family":"Battistoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Maria","family":"Carrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"De Vitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-814833-4.00004-6","article-title":"Epidemiology of diabetes mellitus","volume-title":"Transplantation, bioengineering, and regeneration of the endocrine pancreas","author":"Mekala","year":"2020"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0735-1097(03)00994-X","article-title":"The clinical implications of endothelial dysfunction","volume":"42","author":"Widlansky","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"ref5","first-page":"853","article-title":"Endothelial dysfunction in diabetes mellitus","volume":"3","author":"Hadi","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0229716","DOI":"10.1371\/journal.pone.0229716","article-title":"Does a rise in BMI cause an increased risk of diabetes?: Evidence from India","volume":"15","author":"Gupta","year":"2020","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"238e248","DOI":"10.1016\/j.tem.2018.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns","volume":"29","author":"Lim","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease","volume":"287","author":"Nystrom","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1016\/S0021-9258(19)39030-1","article-title":"Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas","volume":"265","author":"Mojsov","year":"1990","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide, I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.3390\/molecules26164822","article-title":"What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists?\u2014A mini review","volume":"26","author":"Berndt","year":"2021","journal-title":"Molecules"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"19","author":"Marso","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"390","author":"Fr\u00edas","year":"2024","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Inflammation and endothelial dysfunction in diabetes: mechanistic links and therapeutic opportunities","volume":"85","author":"Verma","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Effects of tirzepatide on cardiovascular events in patients with type 2 diabetes","volume":"389","author":"Mann","year":"2023","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12272-019-01180-7","article-title":"Therapeutic targets for endothelial dysfunction in vascular diseases","volume":"42","author":"Huynh","year":"2019","journal-title":"Arch Pharm Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"Addressing the root causes of vascular complications in diabetes: new insights from SGLT2 inhibitors and GLP-1 receptor agonists","volume":"60","author":"Petrie","year":"2023","journal-title":"Acta Diabetol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1509884","DOI":"10.3389\/fmed.2025.1509884","article-title":"Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism","volume":"12","author":"Liu","year":"2025","journal-title":"Front Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.drudis.2006.04.008","article-title":"Vascular NADPH oxidases as drug targets for novel antioxidant strategies","volume":"11","author":"Guzik","year":"2012","journal-title":"Drug Discov Today"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1253\/circj.CJ-11-1015","article-title":"Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction","volume":"75","author":"Heo","year":"2011","journal-title":"Circ J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MOL.0000000000000623","article-title":"Immune\u2013cell interactions and endothelial dysfunction in atherosclerosis and hypertension","volume":"30","author":"Wolf","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00018-016-2442-4","article-title":"Flow signaling and atherosclerosis","volume":"74","author":"Le","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"H2080","DOI":"10.1152\/ajpheart.00917.2020","article-title":"Mitochondrial contributions to vascular endothelial dysfunction, arterial stiffness, and cardiovascular diseases","volume":"320","author":"Kirkman","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE\u2212\/\u2212 mouse model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diab Vasc Dis Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12933-022-01634-1","article-title":"Protective effects of glucagon-like peptide-1 receptor agonists on endothelial dysfunction in diabetes mellitus: a review of preclinical and clinical studies","volume":"21","author":"Xie","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12272-025-01542-4","article-title":"Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases","volume":"48","author":"Heo","year":"2025","journal-title":"Arch Pharm Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41401-020-00589-x","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular protection: from molecular mechanisms to clinical effects","volume":"42","author":"Cheng","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease pathogenesis","volume":"60","author":"Dimitriadis","year":"2019","journal-title":"Hell J Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s11626-024-00947-7","article-title":"Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3\/NF-\u03baB signaling pathway","volume":"60","author":"Shi","year":"2024","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/ATVBAHA.110.222653","article-title":"Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels","volume":"32","author":"Ha","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770937","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1046\/j.1365-201x.1996.446304000.x","article-title":"Distribution of GLP-1 and PACAP receptors in human tissues","volume":"157","author":"Wei","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","article-title":"Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells","volume":"110","author":"Kigoshi","year":"2004","journal-title":"Auton Neurosci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","article-title":"Endothelial dysfunction in type 2 diabetes: molecular mechanisms and therapeutic targets","volume":"23","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.02.003","article-title":"The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose","volume":"94","author":"Salheen","year":"2015","journal-title":"Pharmacol Res"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/life14060690","article-title":"Effect of GLP-1RA treatment on adhesion molecules and monocyte chemoattractant protein-1 in diabetic patients with atherosclerosis","volume":"14","author":"Hachu\u0142a","year":"2024","journal-title":"Life"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","article-title":"Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international Brachial Artery Reactivity Task Force","volume":"39","author":"Corretti","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"117490","DOI":"10.1016\/j.atherosclerosis.2024.117490","article-title":"Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: a network meta-analysis","volume":"391","author":"Kim","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"818537","DOI":"10.3389\/fendo.2022.818537","article-title":"Effects of antidiabetic drugs on endothelial function in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e0135854","DOI":"10.1371\/journal.pone.0135854","article-title":"A comparison of the effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial Sapporo Athero-Incretin Study 2 (SAIS2)","volume":"10","author":"Nomoto","year":"2015","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2019.05.009","article-title":"Exenatide long acting release improves endothelial function and carotid intima-media thickness in patients with type 2 diabetes","volume":"149","author":"Di Paolo","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:02Z","timestamp":1757391482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":65,"alternative-id":["10.3389\/fmed.2025.1669685"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1669685","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1669685"}}